• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Investigation Report on China Insulin Glargine Market, 2009-2018 Product Image

Investigation Report on China Insulin Glargine Market, 2009-2018

  • ID: 2769105
  • February 2014
  • Region: China
  • 40 Pages
  • China Research & Intelligence

FEATURED COMPANIES

  • Aventis Behring GmbH
  • Gan & Lee Pharmaceuticals
  • MORE

With the improvement of people's living standard and changing of lifestyles, as well as deepening of the aging of society, prevalence rate of diabetes keeps rising, making it the third most threatening chronic disease to human health after tumor and cardiovascular disease. Its risk to disable or kill has become a heavy burden on individuals, families, society and governments.

According to statistics from IDF (International Diabetes Federation), the global prevalence rate of diabetes among adults aged 20 to 79 was 8.3% in 2013. The number of diabetes patients has reached 382 million, of which 80% are from medium- and low-income countries where it is still rising rapidly.

It is estimated that by 2035 there will be nearly 592 million people worldwide suffering from diabetes. In the evaluation of diabetes incidence and its trend among various countries and regions, China ranked the first with 98.4 million diabetes patients in 2013, followed by India (65.1 million), the U.S.A. (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that the number of diabetes patients in China will reach 143 million by 2035, which will still be the highest worldwide READ MORE >

FEATURED COMPANIES

  • Aventis Behring GmbH
  • Gan & Lee Pharmaceuticals
  • MORE

1 Relevant Concepts of Insulin Glargine
1.1 Indication
1.2 Sales Status on the Global Market

2 Market Overview of Insulin Glargine in China
2.1 Patent Status
2.2 Major Manufacturers
2.3 Market Size

3 Investigation on Sales Value of Insulin Glargine in China, 2009-2013
3.1 Total Sales Value
3.2 Sales Value by Region

4 Investigation on Market Share of Major Insulin Glargine Manufacturers in China, 2009-2013
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Investigation on Market Size of Insulin Glargine by Dosage Form in China, 2009-2013
5.1 Market Share by Sales Value and Dosage Form
5.2 Market Share by Sales Volume and Dosage Form

6 Reference Price of Insulin Glargine in Hospital Market in China, 2013
6.1 Insulin Glargine (LANTUS) Produced by Aventis Behring GmbH
6.2 Insulin Glargine (Basalin) Produced by Gan & Lee Pharmaceuticals

7 Major Manufacturing Enterprises in China Insulin Glargine Market, 2009-2013
7.1 Aventis Behring GmbH
7.2 Gan & Lee Pharmaceuticals

8 Prospect of China Insulin Glargine Market, 2014-2018
8.1 Trend of Diabetes Incidence
8.2 Forecast on Market Size
8.3 Forecast on Competition Pattern
8.4 Generic Drugs in Research

Selected Charts

Chart Insulin Glargine Products Approved to Market in China, 2014
Chart Sales Value of Insulin Glargine in Global Market, 2009-2013
Chart Sales Value of Insulin Glargine in Hospital Market in China, 2009-2013
Chart Sales Value of Insulin Glargine by Region in China, 2009-2013
Chart Market Share of Insulin Glargine Enterprises by Sales Value in China, 2009-2013
Chart Forecast on Market Size of Hospital-used Insulin Glargine in China, 2014-2018
Chart Price of Insulin Glargine Produced by Aventis Behring GmbH in Hospital Market
Chart Price of Insulin Glargine Produced by Gan & Lee Pharmaceuticals in Hospital Market

- Aventis Behring GmbH
- Gan & Lee Pharmaceuticals

Note: Product cover images may vary from those shown

ALSO AVAILABLE IN THE FOLLOWING LANGUAGES

RELATED PRODUCTS

Our Clients

Our clients' logos